Cerus Corporation Announces Positive Topline Results from Phase 3 RedeS Trial

Cerus Corporation reported positive topline results from its Phase 3 RedeS trial evaluating the INTERCEPT Blood System for red blood cell transfusions. The findings support the potential to extend the company’s pathogen-reduction technology, already used in other blood products, to red blood cells. The article did not provide financial figures or report a stock-price reaction.